With every progressive 12 months, there has been a marked shift in research and development(R&D) pipelines, from traditional small-molecule drug candidates in direction of biologics, oglio-nucleotide-based therapies, PD biomarkers, and different novel compounds that typically combine increased structural complexity with greater susceptibility to disruption and contamination in the course of […]